This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Virtual Symposium: Reducing Cardiovascular Risk: A Paradigm Shift in T2DM Management

Virtual Symposium: Reducing Cardiovascular Risk: A Paradigm Shift in T2DM Management

Format

Webcast

Time to Complete

1 hour

Released

December 31, 2019

Expires

December 31, 2020
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 Credit(s)TM
1.00 / CNE Contact Hour
1.00 / CE for Pharmacists (0.10 CEUs)
1.00 / CPEUs

Accredited Providers

This activity is jointly provided by Annenberg Center for Health Sciences at Eisenhower and CMHC in collaboration with Postgraduate Institute for Medicine

Commercial Supporter

This educational activity is supported by an educational grant from Novo Nordisk.

Program Description

Although the association between type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) remains complex, there is a dire need for comprehensive strategies to reduce the risk of adverse CV events in patients with T2DM. In recent years, several antihyperglycemic agents have shown that they not only improve glycemic parameters, but also reduce the risk of cardiovascular events, as demonstrated in multiple cardiovascular outcome trials (CVOT). These trials, originally designed to demonstrate CV safety, have provided valuable practice-changing insights that have shifted the focus of T2DM care beyond glucose control into CV risk management and prevention.

This symposium will provide clinicians with up-to-date information on the latest outcome trials, how to interpret their clinical practice implications and incorporate this evidence when individualizing therapy for patients with T2DM and cardiovascular risk.

Intended Audience

This activity is designed for US-based endocrinologists, cardiologists, lipidologists, diabetologists, gastroenterologists, hepatologists, PAs, registered nurses, and NPs.

Educational Objectives

  • Discuss the underlying links between CVD and T2DM and the burden of CVD in T2DM patient outcomes
  • Interpret the current evidence from CV outcomes trials with antihyperglycemic agents, including SGLT-2 inhibitors and GLP-1 RAs, and their practice implications in patients with T2DM and CVD
  • Develop individualized treatment regimens based on the latest evidence and guideline recommendations in order to minimize cardiovascular risk in patients with T2DMs

Conflict of Interest Disclosure Policy

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COO they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

Robert H. Eckel, MD (Chair)
Professor of Medicine, Emeritus
Division of Endocrinology, Metabolism and Diabetes
Division of Cardiology
Professor of Physiology and Biophysics, Emeritus
Charles A. Boettcher II Chair in Atherosclerosis
University of Colorado Anschutz Medical Campus
Aurora, CO

Dr. Eckel discloses the following:
Salary: University of Colorado Anschutz Medical Campus
Consulting Fees (e.g., advisory boards): Sanofi/Regeneron, Novo Nordisk, Eli Lilly
Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers’ bureaus): Sanofi/Regeneron – Expert Witness

Lawrence Blonde, MD
Director, Ochsner Diabetes Clinical Research Unit
Frank Riddick Diabetes Institute
Department of Endocrinology
Ochsner Medical Center
New Orleans, LA

Dr. Blonde discloses the following:
Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers’ bureaus): Janssen Pharmaceuticals, Inc., Novo Nordisk, Sanofi
Contracted Research: Grant/Research Support to Dr. Blonde and/or his institution Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Novo Nordisk, and Sanofi
Other Consulting: Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk, Sanofi

Tracy Y. Wang, MD, MHS, MSc
Associate Professor
Director, Health Services Research
Duke University



Dr. Wang discloses the following:
Consulting Fees: AstraZeneca, Sanofi
Contracted Research: AstraZeneca, BMS, Portola, CryoLife, Regeneron

Accredited Provider Disclosures

Charles E. Willis, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower, consults for Pfizer, Inc.; Melissa Velasquez, Accreditation Specialist, also from the Annenberg Center for Health Sciences at Eisenhower, has no relevant commercial relationships to disclose.

The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Cardiometabolic Health Congress. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM  . Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Credit

1.00

Type

CE for Pharmacists

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation Statement

This program is assigned ACPE Universal Activity #0797-9999-19-144-H01-P. This program is designated for up to 1.00 contact hours (0.10 CEUs) of continuing pharmacy education credit. Upon completing the post-survey and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

Type of Activity: Application

Credit

1.00

Type

ANCC Contact Hour(s)

Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation Statement

1.00 contact hours may be earned for successful completion of this activity. Pharmacotherapy contact hours for Advance Practice Registered Nurses is 0.50 hours.

Credit

1.00

Type

CPEU Credit

Accreditation Statement

Postgraduate Institute for Medicine (CDR Provider #3631) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.00 Continuing Professional Education units (CPEUs) for completion of this activity.

This is a Level II activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

For questions about the accreditation of this activity, please visit www.annenberg.net.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue